SARS-CoV-2

In the virus name, SARS stands for "Severe Acute Respiratory Syndrome," reflecting the genetic relatedness (approximately 79% genome sequence identity) to SARS-CoV-1, which caused the 2002–2004 SARS outbreak. The word "corona" derives from the Latin for "crown" or "wreath," referring to the crown-like appearance imparted by the spike glycoproteins on the viral surface. The Coronaviridae Study Group (CSG) of the International Committee on Taxonomy of Viruses (ICTV) assigned the official name on February 11, 2020, the same day the WHO named the disease COVID-19 (Coronavirus Disease 2019). Prior to that, the virus had been provisionally designated "2019 novel coronavirus (2019-nCoV)" (Coronaviridae Study Group, 2020).

Within the ICTV taxonomy, SARS-CoV-2 belongs to the species Severe acute respiratory syndrome-related coronavirus, meaning that SARS-CoV-1 and SARS-CoV-2 are classified under the same species despite being distinct viruses. SARS-CoV-2 is among the pathogens that have elicited the most extensive and rapid scientific response in human history: within just 11 months of the virus genome sequence being published, the first vaccine received emergency use authorization.

The taxonomic position of SARS-CoV-2 is as follows:

The family Coronaviridae is divided into four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. SARS-CoV-2 belongs to Betacoronavirus, alongside SARS-CoV-1, MERS-CoV, and the common-cold coronaviruses HCoV-OC43 and HCoV-HKU1. Within the subgenus Sarbecovirus, SARS-CoV-2 is most closely related to the bat coronavirus RaTG13, sharing 96.2% whole-genome sequence identity (Zhou et al., 2020). Under the Baltimore classification system, SARS-CoV-2 is a Group IV virus (+ssRNA), meaning its genome can directly serve as messenger RNA for translation by host ribosomes.

Since its emergence, SARS-CoV-2 has undergone continuous evolution, yielding multiple VOCs: Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil), Delta (B.1.617.2, India), and Omicron (B.1.1.529, South Africa/Botswana). As of February 2026, JN.1 remains designated as a variant of interest (VOI) by the WHO, and current variants under monitoring (VUMs) include KP.3.1.1, NB.1.8.1, XFG, and BA.3.2 (WHO, 2026). Recombination is an important mechanism in coronavirus evolution, and recombinant sublineages such as XBB, XFG, and XFZ have been documented (Markov et al., 2023).

SARS-CoV-2 virions are roughly spherical to pleomorphic, enveloped particles measuring approximately 60–140 nm in diameter (mean ~80–120 nm by cryo-EM) (Yao et al., 2020). The viral surface is studded with characteristic club-shaped spike projections approximately 9–12 nm in length, giving the virion a solar-corona-like appearance.

The virus possesses four major structural proteins. The spike (S) glycoprotein (~180–200 kDa) forms homotrimers that project from the envelope surface, mediating receptor binding and membrane fusion. The membrane (M) protein (222 amino acids) is the most abundant envelope protein and plays a central role in virus assembly. The envelope (E) protein (75 amino acids) is present in small quantities but is essential for assembly, release, and exhibits ion channel activity. The nucleocapsid (N) protein (419 amino acids) binds the viral RNA to form a helical ribonucleoprotein (RNP) complex (V'kovski et al., 2021).

The spike protein consists of 1,273 amino acids and is cleaved into the S1 subunit (receptor binding) and S2 subunit (membrane fusion). Within S1, the receptor-binding domain (RBD) contains the receptor-binding motif (RBM), which directly interacts with the host cell ACE2 receptor. A distinctive feature of SARS-CoV-2 is a four-amino-acid insertion (PRRA) at the S1/S2 boundary that creates a furin cleavage site (RRAR), absent in other sarbecoviruses, which may contribute to enhanced transmissibility (Coutard et al., 2020). Additionally, each spike protein monomer carries approximately 22 N-linked glycans, shielding roughly 40% of the protein surface in a "glycan shield" that facilitates immune evasion (Watanabe et al., 2020).

The SARS-CoV-2 genome consists of approximately 29,903 nucleotides (~29.9 kb) of positive-sense, single-stranded RNA, making it among the largest genomes of all RNA viruses. The genome features a 5' methylated cap and a 3' poly(A) tail. From 5' to 3', the gene order is: 5'-UTR — ORF1a/ORF1b (replicase) — S (spike) — E (envelope) — M (membrane) — N (nucleocapsid) — 3'-UTR (Wu et al., 2020; Lu et al., 2020).

ORF1a/ORF1b occupies approximately two-thirds of the genome and encodes two polyproteins (pp1a and pp1ab) via a -1 ribosomal frameshift mechanism. These polyproteins are processed by two viral proteases—the papain-like protease (PLpro, nsp3) and the main protease (Mpro/3CLpro, nsp5)—into 16 non-structural proteins (nsp1–16). Key non-structural proteins include the RNA-dependent RNA polymerase (RdRp, nsp12), helicase (nsp13), and the proofreading exoribonuclease (ExoN, nsp14). The ExoN activity of nsp14 confers SARS-CoV-2 a relatively low mutation rate of approximately 1 x 10^-6 to 2 x 10^-6 substitutions per nucleotide per replication cycle, low by RNA virus standards (V'kovski et al., 2021).

Despite this relatively low per-replication mutation rate, the enormous global scale of infection has allowed extensive mutational accumulation, particularly in the spike protein where mutations are linked to immune evasion and altered transmissibility. Recombination further drives coronavirus evolution, with recombinant lineages such as XBB, XFG, and XFZ having been identified (Markov et al., 2023).

Infection begins when the spike protein binds to the ACE2 receptor on host cell surfaces. The host transmembrane serine protease TMPRSS2 then cleaves the spike protein to facilitate membrane fusion, or alternatively the virus enters via the endosomal pathway where cathepsin L mediates activation (Hoffmann et al., 2020). ACE2 is expressed in pulmonary epithelial cells, intestinal epithelial cells, renal proximal tubular cells, cardiomyocytes, and endothelial cells, enabling multi-organ involvement. The binding affinity of the SARS-CoV-2 RBD for ACE2 is approximately 10–20-fold higher than that of SARS-CoV-1, providing a molecular basis for its high transmissibility (Wrapp et al., 2020).

COVID-19 symptoms range from asymptomatic to fatal. The most common symptoms include fever (83–98%), cough (59–82%), fatigue (44–70%), anosmia/ageusia (34–59%), and dyspnea (31–40%). Approximately 80% of infections are mild to moderate, ~15% progress to severe disease requiring supplemental oxygen, and ~5% become critical requiring intensive care. Severe complications include acute respiratory distress syndrome (ARDS), sepsis, multi-organ failure, and thromboembolic events. A characteristic hyperinflammatory state ("cytokine storm") involving elevated IL-6, IL-1-beta, and TNF-alpha has been documented (Harrison et al., 2020).

Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID, refers to symptoms persisting or newly emerging beyond 4 weeks after acute infection. Key symptoms include profound fatigue, cognitive impairment ("brain fog"), dyspnea, chest pain, and palpitations. An estimated 10–20% of adults experience Long COVID (Parotto et al., 2023). High-risk groups for severe disease include adults aged 65 and older, individuals with diabetes, cardiovascular disease, chronic lung disease, obesity (BMI >=30), and immunocompromised states.

Diagnosis relies on real-time reverse transcription polymerase chain reaction (RT-PCR) as the gold standard, with rapid antigen tests (RATs) widely used for mass screening and self-testing. Serological assays (antibody tests) serve to confirm prior infection or vaccination status.

SARS-CoV-2 is transmitted primarily via respiratory droplets and aerosols generated when an infected person breathes, talks, coughs, or sneezes. Aerosol transmission is particularly important in poorly ventilated indoor environments. Contact transmission (touching contaminated surfaces followed by mucous membrane contact) is a possible but minor route.

The incubation period averaged approximately 5 days (range 2–14 days) for the original strain but shortened to approximately 3 days with the Omicron variant (Lauer et al., 2020). Infectiousness begins 1–2 days before symptom onset, peaks during the first few days of illness, and generally persists for 8–10 days after symptom onset, though it may last longer in immunocompromised individuals. Asymptomatic transmission has been a major challenge for pandemic control.

The basic reproduction number (R0) has varied markedly across variants: approximately 2.5–3.0 for the original Wuhan strain, ~5–6 for Delta, and ~9.5–18 for Omicron. Regarding environmental stability, SARS-CoV-2 remained viable in aerosols for up to 3 hours, on copper for 4 hours, on cardboard for 24 hours, and on stainless steel and plastic for up to 72 hours under laboratory conditions (van Doremalen et al., 2020). The virus is rapidly inactivated by common disinfectants including 70% ethanol, 0.5% hydrogen peroxide, and 0.1% sodium hypochlorite.

Key approved antiviral agents for COVID-19 include Paxlovid (nirmatrelvir/ritonavir), remdesivir (Veklury), and molnupiravir (Lagevrio). Paxlovid, an oral inhibitor of the SARS-CoV-2 main protease (Mpro), reduced hospitalization and death by approximately 89% in high-risk patients when administered within 5 days of symptom onset (Hammond et al., 2022). For severe disease, dexamethasone and other corticosteroids, IL-6 receptor antagonists (tocilizumab, sarilumab), and the JAK inhibitor baricitinib have demonstrated mortality benefits (RECOVERY Collaborative Group, 2021).

COVID-19 vaccine development proceeded at unprecedented speed, with the first emergency use authorization granted in December 2020. Major vaccine platforms include mRNA vaccines (Pfizer-BioNTech BNT162b2/Comirnaty, Moderna mRNA-1273/Spikevax), viral vector vaccines (AstraZeneca ChAdOx1, Janssen Ad26.COV2.S), inactivated vaccines (Sinovac CoronaVac, Sinopharm BBIBP-CorV), and protein subunit vaccines (Novavax NVX-CoV2373/Nuvaxovid). Over 13 billion vaccine doses were administered globally during the pandemic, and the WHO estimated that vaccines prevented approximately 14.4 million deaths in 2021 alone.

For the 2025–2026 respiratory season, updated vaccines have been formulated to target the Omicron JN.1 lineage. The U.S. FDA recommended JN.1-lineage-based monovalent formulations in May 2025. Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax/mNEXSPIKE) target the LP.8.1 subvariant (a JN.1 descendant), while Novavax (Nuvaxovid) targets the JN.1 lineage, all receiving FDA approval in August 2025 for the 2025–2026 season (FDA, 2025; CDC, 2025). Non-pharmaceutical interventions—mask-wearing, hand hygiene, improved ventilation—have also proven effective for reducing transmission.

SARS-CoV-2 is presumed to have a zoonotic origin, with horseshoe bats (Rhinolophus spp.) considered the most likely natural reservoir. The bat coronavirus RaTG13 shares 96.2% genome identity with SARS-CoV-2, though the direct ancestor has not been identified (Zhou et al., 2020). Pangolin coronaviruses with RBDs highly similar to SARS-CoV-2 have been proposed as evidence for a possible intermediate host, but this remains unconfirmed. A recent phylogenetic study estimated that the closest bat virus ancestor of SARS-CoV-2 existed within approximately 10 years of the human emergence event (Pekar et al., 2025).

SARS-CoV-2 can infect a wide range of animal species, predominantly through reverse zoonosis (human-to-animal spillover). Natural infections have been documented in cats, dogs, ferrets, mink, lions, tigers, gorillas, hamsters, and white-tailed deer, among others. Mass outbreaks on mink farms, particularly in Denmark and the Netherlands, resulted in mink-to-human spillback events and the culling of millions of animals. Notably, white-tailed deer (Odocoileus virginianus) populations in the United States have shown seroprevalence rates up to 40%, raising concerns that wildlife may serve as a persistent viral reservoir with the potential for independent viral evolution.

Following reports of unexplained pneumonia cases in Wuhan in December 2019, Chinese researchers published the complete viral genome sequence in January 2020, catalyzing a global research response (Wu et al., 2020). On February 11, 2020, the ICTV CSG named the virus SARS-CoV-2, while the WHO designated the disease COVID-19 (Coronaviridae Study Group, 2020). The mRNA vaccine platform, which had not been approved for any human vaccine prior to the pandemic, was validated by the success of the Pfizer-BioNTech and Moderna vaccines—the culmination of decades of foundational research. This technology is now being applied to vaccine development for cancer, influenza, HIV, and other diseases.

SARS-CoV-2 research has advanced at an extraordinary pace across structural biology (cryo-EM elucidation of the spike protein), immunology (immune evasion and hybrid immunity), epidemiology (variant surveillance systems), and antiviral drug development (Mpro and RdRp inhibitors). In 2024, the WHO launched CoViNet (WHO Coronavirus Network) to strengthen international collaboration for early coronavirus detection and variant tracking.

Key unresolved questions include the precise origin of the virus (natural spillover vs. laboratory incident hypotheses), the pathophysiology and treatment of Long COVID, prediction of future variant emergence, the public health implications of wildlife reservoirs, and the development of pan-coronavirus vaccines.

SARS-CoV-2 has the lowest case fatality rate among the three but by far the highest transmissibility, resulting in total case and death counts that vastly exceed those of SARS-CoV-1 and MERS-CoV combined. All three viruses are presumed to have originated in bats, but their intermediate hosts and routes of human spillover differ.

Baden, L.R., El Sahly, H.M., Essink, B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 384(5), 403–416. https://doi.org/10.1056/NEJMoa2035389

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology, 5(4), 536–544. https://doi.org/10.1038/s41564-020-0695-z

Coutard, B., Valle, C., de Lamballerie, X., et al. (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Research, 176, 104742. https://doi.org/10.1016/j.antiviral.2020.104742

Hammond, J., Leister-Tebbe, H., Gardner, A., et al. (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine, 386(15), 1397–1408. https://doi.org/10.1056/NEJMoa2118542

Harrison, A.G., Lin, T., & Wang, P. (2020). Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in Immunology, 41(12), 1100–1115. https://doi.org/10.1016/j.it.2020.10.004

Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052

Hu, B., Guo, H., Zhou, P., & Shi, Z.L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 19(3), 141–154. https://doi.org/10.1038/s41579-020-00459-7

Lauer, S.A., Grantz, K.H., Bi, Q., et al. (2020). The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases. Annals of Internal Medicine, 172(9), 577–582. https://doi.org/10.7326/M20-0504

Lu, R., Zhao, X., Li, J., et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus. The Lancet, 395(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8

Markov, P.V., Ghafari, M., Beer, M., et al. (2023). The evolution of SARS-CoV-2. Nature Reviews Microbiology, 21(6), 361–379. https://doi.org/10.1038/s41579-023-00878-2

Msemburi, W., Karlinsky, A., Knutson, V., et al. (2023). The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature, 613(7942), 130–137. https://doi.org/10.1038/s41586-022-05522-2

Parotto, M., Gyongyosi, M., Howe, K., et al. (2023). Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. The Lancet Respiratory Medicine, 11(8), 739–754. https://doi.org/10.1016/S2213-2600(23)00159-8

Pekar, J.E., Magee, A., Parker, E., et al. (2025). The recency and geographical origins of the bat viruses ancestral to SARS-CoV and SARS-CoV-2. Cell, 188(8), 1674–1689.

Polack, F.P., Thomas, S.J., Kitchin, N., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577

RECOVERY Collaborative Group. (2021). Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 384(8), 693–704. https://doi.org/10.1056/NEJMoa2021436

V'kovski, P., Kratzel, A., Steiner, S., et al. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Microbiology, 19(3), 155–170. https://doi.org/10.1038/s41579-020-00468-6

van Doremalen, N., Bushmaker, T., Morris, D.H., et al. (2020). Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine, 382(16), 1564–1567. https://doi.org/10.1056/NEJMc2004973

Wang, H., Paulson, K.R., Pease, S.A., et al. (2022). Estimating excess mortality due to the COVID-19 pandemic. The Lancet, 399(10334), 1513–1536. https://doi.org/10.1016/S0140-6736(21)02796-3

Watanabe, Y., Allen, J.D., Wrapp, D., McLellan, J.S., & Crispin, M. (2020). Site-specific glycan analysis of the SARS-CoV-2 spike. Science, 369(6501), 330–333. https://doi.org/10.1126/science.abb9983

Wrapp, D., Wang, N., Corbett, K.S., et al. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263. https://doi.org/10.1126/science.abb2507

Wu, F., Zhao, S., Yu, B., et al. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/10.1038/s41586-020-2008-3

Yao, H., Song, Y., Chen, Y., et al. (2020). Molecular Architecture of the SARS-CoV-2 Virus. Cell, 183(3), 730–738.e13. https://doi.org/10.1016/j.cell.2020.09.018

Zhou, P., Yang, X.L., Wang, X.G., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7

World Health Organization. (2026). Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants

NIH Office of Science Policy. (2025). Biosafety Considerations for Research Involving SARS-CoV-2. https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/biosafety-considerations-for-research-involving-sars-cov-2/

U.S. Food and Drug Administration. (2025). COVID-19 Vaccines (2025-2026 Formula) for Use in the United States. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025